Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors
Chimeric antigen receptor (CAR) T-cell therapy entails the genetic engineering of a patient’s T-cells to express membrane spanning fusion receptors with defined specificities for tumor-associated antigens. These CARs are capable of eliciting robust T-cell activation to initiate killing of the target...
Main Authors: | Paris Kosti, John Maher, James N. Arnold |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-05-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2018.01104/full |
Similar Items
-
New Chimeric Antigen Receptor Design for Solid Tumors
by: Yuedi Wang, et al.
Published: (2017-12-01) -
Chimeric Antigen Receptor-Engineered T Cells in Tumor Immunotherapy: From Bench to Beside
by: Peng WANG
Published: (2017-06-01) -
Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors
by: Erhao Zhang, et al.
Published: (2018-01-01) -
Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications
by: Hamid R. Mirzaei, et al.
Published: (2017-12-01) -
Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward
by: Leila Jafarzadeh, et al.
Published: (2020-04-01)